



KENTUCKY PUBLIC PENSIONS AUTHORITY

David L. Eager, Executive Director

1260 Louisville Road • Frankfort, Kentucky 40601
kyret.ky.gov • Phone: 502-696-8800 • Fax: 502-696-8822



February 29, 2024

Ms. Katie Carney
Executive Assistant, Director's Office
Legislative Research Commission
Capitol Annex, Room 186
Frankfort, KY 40601

RE: House Bill 713 (2024 RS BR 1629)
AA Statement Required by KRS 6.350
AA Statement 1 and 2 of 5

Dear Ms. Carney:

House Bill 713 (2024 RS BR 1629) creates a new section of Subtitle 17A of Kentucky Revised Statute Chapter 304 to require health benefit plans to provide coverage for FDA-approved prescription drugs for the treatment of postpartum mood disorders; amends KRS 164.2871, 205.522, 205.6485, and 18A.225 to require a self-insured employer group health plan provided by a state postsecondary education institution to its employees, Medicaid, and Kentucky Children's Health Insurance Program to comply with the new section on postpartum mood disorder coverage; and directs that provisions apply to health benefit plans issued on or after January 1, 2025. This bill is effective January 1, 2025.

Kentucky Public Pensions Authority (KPPA) staff members have examined House Bill 713 (2024 RS BR 1629). We have determined that the bill will not increase or decrease benefits, nor will it increase or decrease the participation in benefits, in any of the retirement systems administered by the Kentucky Public Pensions Authority. House Bill 713 (2024 RS BR 1629) will not change the actuarial accrued liability of any of the systems administered by KPPA.

In accordance with KRS 6.350 (2)(c), Kentucky Public Pensions Authority certifies the following:

1. The estimated number of individuals potentially affected as of June 30, 2023, are 421,609 active, inactive, and retired members in the plans administered by KPPA;
2. There is no estimated change in benefit payments;
3. There may be an increase in employer costs if the change increases insurance premiums for the plans offered by the KPPA; and
4. There is no estimated change in administrative expenses.

We have not requested any further actuarial analysis of House Bill 713 (2024 RS BR 1629) by the KPPA's independent actuary.

Please let me know if you have any questions regarding our analysis of House Bill 713 (2024 RS BR 1629).

Sincerely,

A handwritten signature in black ink that reads "David Eager". The signature is written in a cursive style with a large, prominent initial "D".

David L. Eager, Executive Director
Kentucky Public Pensions Authority

March 6, 2024

Ms. Katie Carney

Director's Office

Legislative Research Commission

Capitol Annex, Room 104

Frankfort, KY 40601

RE: HB 713 - AN ACT relating to coverage for the treatment of postpartum mood disorders.

AA Statement 3 and 4 of 5

Dear Ms. Carney:

HB 713 (BR 1629) would create a new section of Subtitle 17A of KRS Chapter 304 to require health benefit plans to provide coverage for FDA-approved prescription drugs for the treatment of postpartum mood disorders; amend KRS 164.2871, 205.522, 205.6485, and 18A.225 to require a self-insured employer group health plan provided by a state postsecondary education institution to its employees, Medicaid, and Kentucky Children's Health Insurance Program to comply with the new section on postpartum mood disorder coverage; direct that provisions apply to health benefit plans issued on or after January 1, 2025.

Staff of the Judicial Form Retirement System (JFRS) has reviewed **HB 713 (BR 1629)** and determined it would not materially increase or decrease benefits, or increase or decrease participation in benefits, or change the current actuarial liability of either plan administered by JFRS. The requirements outlined in the legislation could cause an increase to insurance premiums for the plans provided through JFRS, but that is not easily measurable at this time.

In compliance with KRS 6.350(2)(c), the Judicial Form Retirement Systems (the agency in charge with the administration of JRP and LRP) certifies the following:

1. The estimated number of participants potentially affected, as of June 30, 2023, are 1,018 individuals participating in JRP or LRP.
2. There is no estimated change in benefits.

3. There is no estimated change to current employer costs; however, however, if the requirements outlined in the legislation increased insurance premiums, there could be an increase in employer cost.
4. There is no estimated change to administrative expenses.

We have not requested any further actuarial analysis of **HB 713 (BR 1629)** by the Systems' independent actuary. Please let me know if you have any questions regarding this analysis.

Sincerely,

A handwritten signature in cursive script that reads "Bo Cracraft".

Bo Cracraft,

Executive Director